ÂÜÀòÂÒÂ×

Riccardo Braglia serves as Executive Chairman of Helsinn Group, overseeing its transformation into a fully integrated targeted therapy company focused on improving patient outcomes globally. With extensive experience in the pharmaceutical industry, Riccardo has held multiple leadership roles within the Helsinn Group, including Chairman of the Board for Helsinn Therapeutics and Vice Chairman and Group CEO. Additional positions include Board Member at Fondazione Helmut Horten, Chief Executive Officer of 3B Future Holding SA, and Member of the Board at Medacta International and the Conquer Cancer Foundation of ASCO. An advocate for healthcare innovation, Riccardo also co-founded Sinomedica and serves as a Board Member for HAS Healthcare Advanced Synthesis SA. Educational credentials include an MBA from Università Bocconi and ongoing executive education programs at Harvard Medical School.